FAAH Inhibitor Trials Could Resume In US Following French Study Disaster Review
Executive Summary
Bial-Portela's drug had 'unique toxicity' not found with other compounds in the class, FDA says; findings could allow studies of Janssen's and Pfizer's investigational FAAH inhibitors that have been on hold to proceed.